Suven Life Sciences Completes Patient Enrollment for Alzheimer's Drug Study
Suven Life Sciences announced the completion of patient enrollment in its global Phase-3 clinical study for Masupirdine (SUVN-502), a potential treatment for agitation associated with Alzheimer's Dementia (AAD). The study, conducted across the USA and Europe, randomized 424 patients, exceeding the initial target of 375. The Last Patient Last Visit (LPLV) is anticipated by December 2026, with database lock expected by March 2027 and topline results by May 2027. Masupirdine is a selective 5-HT6 receptor antagonist aiming to offer a differentiated treatment option compared to existing sedatives or antipsychotics, which have significant limitations in this vulnerable patient population. The company's management expressed optimism about the study's completion and the potential of Masupirdine to address a significant unmet need.
Key Highlights
- Patient enrollment completed for global Phase-3 study of Masupirdine (SUVN-502).
- 424 patients randomized, exceeding the target of 375.
- Topline results for the Alzheimer's drug study are expected by May 2027.
- Masupirdine targets agitation associated with Alzheimer's Dementia (AAD).
- Study conducted across USA and Europe with no safety concerns observed to date.
Price Impact
More from SUVEN